Furthermore, ongoing developments on the use of GLP-1 receptor agonists beyond diabetes in neurodegenerative diseases, cardiovascular conditions, and even obstructive sleep apnea, are propelling the global GLP-1 receptor agonist market growth
Fiorentino TV, Owston M, Abrahamian G,et al
However, Novo Nordisk has discontinued Saxenda to focus its manufacturing capacity on newer medications, like Wegovy
It was going to be close
Key Takeaways While both contain semaglutide, Wegovy is approved specifically for weight management, whereas Ozempic is approved for the treatment of type 2 diabetes
When sourced from reputable providers, they work identically